In a single-center study of patients with BCR-ABL-positive leukemias, the percentages of patients in CP, AP, or blast phase (BP) CML with imatinib resistance were 29%, 45%, and 92%, respectively [18]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.